News

Gerlud explains unmet needs in EPI, including underdiagnosed patient populations, and the intense pill burdens patients face.

Analysis of 75,064 UK Biobank participants found late-onset depression associated with worse fluid intelligence and visuospatial memory and a 42–52% increased dementia risk.

In this segment of his interview, Passeron speaks on the next steps for upadacitinib in non-segmental vitiligo (NSV).

The Agency approved Lilly’s orforglipron (Foundayo) for adults with obesity or overweight. It can be taken any time of the day without restrictions on food and water intake.

Chan describes the current landscape of dialysis care and why home-based approaches are gaining momentum for patients with ESRD.

A study shows that weekly or daily throat clearing, hoarseness, and voice strain are more common among those with diagnosed respiratory allergies, particularly among women.

FDA approvals broaden ALYFTREK and TRIKAFTA eligibility to nearly 95% of US cystic fibrosis patients using a functional, mechanism-based variant criterion.

Hosts break down the latest updates in mineralocorticoid receptor agonists, including the SPIRIT-HF trial and announcements from the finerenone program.

Experts reflect on how advances in understanding CLE have fueled drug development and what the trajectory of innovation holds for the field.

Experts explore how litifilimab's BDCA2-targeting mechanism maps onto CLE pathophysiology.

Experts discuss how an approved targeted therapy could restructure collaboration between dermatology and rheumatology.

Experts examine why the CLASI and CLA-IGA-R reflect the true burden of CLE.

With no targeted therapies approved in more than 70 years, new phase 2 AMETHYST data for litifilimab may signal a turning point for CLE.

Merola discussed how new data from AAD 2026 suggest broader anti-inflammatory properties of GIP/GLP-1 RAs may offer benefits beyond weight loss.

Blauvelt discussed highlights from the phase 3 ONWARD1 and ONWARD2 clinical trials presented at AAD 2026.

Phase 3 data on rademikibart in moderate-to-severe atopic dermatitis (AD) have been released from the AAD late-Breaking research session.

These data from REMIX-1 and 2 suggest remibrutinib, in those with chronic spontaneous urticaria (CSU), can lead to fast, early symptom control.

Deep learning applied to routine ECGs identifies subtle cardiac signals linked to early COPD, potentially enabling earlier diagnosis and intervention.

This interview highlights phase 3 findings on sonelokimab for individuals with hidradenitis suppurativa (HS).

Garimella discusses the history, clinical impact, and rationale for removing race-based GFR from clinical decision-making.

Inhaled GH001 achieved 57.5% remission by day 8 in TRD with a large effect size vs placebo; Thase discusses interpretation, unblinding, and phase 3 implications.

Laurel Messer, PhD, RN, joins the show to provide insight into the latest updates from Tandem Diabetes Care.

David Cherney, MD, PhD, discusses REMODEL trial insights into how semaglutide reduces albuminuria and impacts kidney fat and fibrosis pathways.

Martin de Borst, MD, PhD, discusses IV iron use in transplant recipients through an RCT focused on exercise capacity, function, and quality of life.

REMODEL reveals how semaglutide protects kidneys, showing reduced inflammation, improved vascular health, and evidence of structural repair in diabetic CKD.

This interview highlights new 12-month, real-world data on tralokinumab and its long-term efficacy in patients with skin of color who live with atopic dermatitis.

Patients with non-segmental vitiligo (NSV) on upadacitinib versus placebo showed continuous improvement over 48 weeks with no plateau.

As patients increasingly turn to ChatGPT for mental health support, psychiatrists and ethicists weigh the clinical risks, ethical concerns, and what clinicians should do next.